Advertisement

Search Results

Advertisement



Your search for Syed Ali Abutalib, MD, and David L. Porter, MD matches 3 pages

Showing 1 - 3


hematologic malignancies
immunotherapy

Answers to Hematology Expert Review Questions

Question 1 Which of the following statements about cytokine-release syndrome and neurotoxicity after tisagenlecleucel infusion is correct? Correct answer: B. The median time to onset of cytokine-release syndrome is 3 days. Expert Perspective Following tisagenlecleucel infusion, cytokine-release...

hematologic malignancies
immunotherapy

CAR T-Cell Gene Therapy: Toxicities and Management Principles

“Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.”                                                                                                                  —Marie Curie The ASCO Post is pleased to present Hematology ...

lymphoma

Update on FDA-Approved CAR T-Cell Gene Therapy for B-Cell Lymphomas

On October 18, 2017, the U.S. Food and Drug Administration (FDA) granted approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Specifically, this treatment can be used after two or more lines of systemic therapy for diffuse...

Advertisement

Advertisement




Advertisement